LOXL2 and lung cancer: Our previous studies have shown that restoration of the miR-29 family significantly inhibits cancer cell aggressiveness through targeting lysyl oxidase like-2 (LOXL2) in HNSCC, renal cell carcinoma, and lung cancer [11, 20, 21].